Genetic variations may predict lung cancer treatment response

09 August 2013

People who inherit certain gene faults may be less likely to survive lung cancer, a study has found.

Researchers at the Moffitt Cancer Centre in the US studied samples from 651 patients with non-small-cell lung cancer and discovered four survival-related genetic variations that were located on a single inflammation-related gene called TNFRSF10B.

They found that these variants increased patients' risk of death by up to 41 per cent.

In addition, patients with these gene variations were more likely to die if they were not given chemotherapy treatment after surgery than if their cancer treatment included both surgery and chemotherapy.

Lead study author Dr Matthew Schabath, whose findings are published in the journal Carcinogenesis, said there are few confirmed biomarkers for predicting survival or cancer treatment response in these patients.

"Having a validated genetic biomarker based on inherited differences in our genes may allow physicians to determine the best treatments for an individual patient based on their unique genetics," he added.

Posted by Philip Briggs


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)